Tokyo Tape
Sign in
← Nihon Chouzai

Half-year report · Q2

3341.TEDINET S100URMJ
Period2024-04-01 → 2024-09-30
Filed2024-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥175.6bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥340.3bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥166.3bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥423m2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥3.4bn2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income¥772m2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥9.4bn2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥3.4bn2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax¥762m2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥3.4bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)−¥43m2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥2.6bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.7bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income−¥43m2024-04-01 → 2024-09-30Cons.Profit loss
Net income¥1.7bn2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥204.1bnat 2024-09-30Cons.Assets
Total assets¥195.1bnat 2024-03-31Cons.Assets
Total assets¥193.5bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥146.3bnat 2024-09-30Cons.Liabilities
Total liabilities¥136.7bnat 2024-03-31Cons.Liabilities
Net assets / equity¥57.9bnat 2024-09-30Cons.Net assets
Net assets / equity¥58.4bnat 2024-03-31Cons.Net assets
Net assets / equity¥57.9bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥26.4bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥26.0bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥26.4bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥26.0bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥22.2bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥23.8bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow¥1.6bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥20.4bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥11.9bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥6.0bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥13.7bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥8.0bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥4.8bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥4.4bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥5.4bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-1.442024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥85.352023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥58.442023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio28.3%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio29.9%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio29.9%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 36
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥6.6bn
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥6.6bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥4.2bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥156.6bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥156.6bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥4.5bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥6.0bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥5.9bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥122m
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥766m
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥19.6bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥13.1bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥6.5bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentsegment profit2024-04-01 → 2024-09-30−¥652m
Total Of Reportable Segments And Otherssegment totalrevenue2024-04-01 → 2024-09-30¥182.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2024-04-01 → 2024-09-30¥175.6bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2024-04-01 → 2024-09-30¥6.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2024-04-01 → 2024-09-30¥4.6bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥6.7bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥6.7bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥3.5bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥147.6bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥147.6bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥6.0bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥4.9bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥4.9bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥14m
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥698m
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥20.5bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥13.8bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥6.7bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥167m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥173.0bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥166.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥6.7bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥6.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 520
ItemContextValueUnit
Retirement benefit expenses sgaPrior1YTDDuration103000000JPY
Retirement benefit expenses sgaCurrentYTDDuration118000000JPY
Provision for directors retirement benefits sgaPrior1YTDDuration9000000JPY
Provision for directors retirement benefits sgaCurrentYTDDuration8000000JPY
Research and development expenses sgaPrior1YTDDuration1306000000JPY
Research and development expenses sgaCurrentYTDDuration1733000000JPY
Rent expenses sgaPrior1YTDDuration1093000000JPY
Rent expenses sgaCurrentYTDDuration1402000000JPY
Consumption taxes sgaPrior1YTDDuration11520000000JPY
Consumption taxes sgaCurrentYTDDuration12276000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E05422-000DispensingPharmacyBusinessReportableSegmentsMember147605000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E05422-000PharmaceuticalManufacturingAndSalesBusinessReportableSegmentsMember13773000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E05422-000MedicalProfessionalStaffingAndPlacementBusinessReportableSegmentsMember4931000000JPY
Revenues from external customersPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember166310000000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration166310000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E05422-000DispensingPharmacyBusinessReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E05422-000PharmaceuticalManufacturingAndSalesBusinessReportableSegmentsMember6713000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E05422-000MedicalProfessionalStaffingAndPlacementBusinessReportableSegmentsMember14000000JPY
Transactions with other segmentsPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember6728000000JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember-6728000000JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E05422-000DispensingPharmacyBusinessReportableSegmentsMember147605000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E05422-000PharmaceuticalManufacturingAndSalesBusinessReportableSegmentsMember20487000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E05422-000MedicalProfessionalStaffingAndPlacementBusinessReportableSegmentsMember4945000000JPY
Net salesPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember173038000000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember-6728000000JPY
Net salesPrior1YTDDuration166310000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E05422-000DispensingPharmacyBusinessReportableSegmentsMember6016000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E05422-000PharmaceuticalManufacturingAndSalesBusinessReportableSegmentsMember167000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E05422-000MedicalProfessionalStaffingAndPlacementBusinessReportableSegmentsMember698000000JPY
Operating incomePrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember6882000000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember-3484000000JPY
Operating incomePrior1YTDDuration3397000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E05422-000DispensingPharmacyBusinessReportableSegmentsMember156569000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E05422-000PharmaceuticalManufacturingAndSalesBusinessReportableSegmentsMember13105000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E05422-000MedicalProfessionalStaffingAndPlacementBusinessReportableSegmentsMember5899000000JPY
Revenues from external customersCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember175575000000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration175575000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E05422-000DispensingPharmacyBusinessReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E05422-000PharmaceuticalManufacturingAndSalesBusinessReportableSegmentsMember6464000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E05422-000MedicalProfessionalStaffingAndPlacementBusinessReportableSegmentsMember122000000JPY
Transactions with other segmentsCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember6586000000JPY
Transactions with other segmentsCurrentYTDDuration_ReconcilingItemsMember-6586000000JPY
Transactions with other segmentsCurrentYTDDuration－JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E05422-000DispensingPharmacyBusinessReportableSegmentsMember156569000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E05422-000PharmaceuticalManufacturingAndSalesBusinessReportableSegmentsMember19570000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E05422-000MedicalProfessionalStaffingAndPlacementBusinessReportableSegmentsMember6021000000JPY
Net salesCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember182161000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identityconsolidated 2024-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass